FDA On Personalized Medicine: Don’t Skimp On Diagnostic Quality Development
This article was originally published in The Gray Sheet
Executive Summary
A CDRH representative tells a conference on drug/diagnostic co-development that it doesn’t matter how well designed a study for a therapeutic agent is if the accompanying biomarker-targeted test is not reliable and uniformly implemented.